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Hypothermia is a condition inwhich core temperature drops below the level necessary tomaintain bodily functions.The decrease in
temperaturemay disrupt some physiological systems of the body, including alterations inmicrocirculation and reduction of oxygen
supply to tissues. The lack of oxygen can induce the generation of reactive oxygen and nitrogen free radicals (RONS), followed by
oxidative stress, and finally, apoptosis and/or necrosis. Furthermore, since the hypothermia is inevitably followed by a rewarming
process, we should also consider its effects. Despite hypothermia and rewarming inducing injury, many benefits of hypothermia
have been demonstrated when used to preserve brain, cardiac, hepatic, and intestinal function against ischemic injury. This review
gives an overview of the effects of hypothermia and rewarming on the oxidant/antioxidant balance and provides hypothesis for the
role of reactive oxygen species in therapeutic hypothermia.
1. Introduction
Hypothermia has been known as a possible therapeutic
tool for millennia. However, it has only been used more
systematically in the last two centuries, and it is recently that
we have started to understand some of its mechanisms of
action and side effects.
1.1. Characterization of Hypothermia. Normal body temper-
ature in humans is maintained near a constant level of 36.5–
37.5∘C through homeostatic processes of thermoregulation.
The hypothalamus controls body temperature through the
preoptic and the posterior nuclei. The posterior nucleus is
especially important, since it acts in regulating the physio-
logical responses that allow the control of body temperature,
such as vasoconstriction, shivering or increased intake of
food to warm-up, sweating, and vasodilation. Heat is mainly
generated in muscle tissue, including other thermogenic
organs such as the heart and the liver, while it is lost
through the skin (90%) and lungs (10%) and its rate is
influenced by the physics involved in the mechanisms of
convection, conduction, evaporation, and radiation [1]. In
small mammals the brown adipose tissue (BAT) is known to
act as a thermogenic organ allowing nonshivering thermo-
genesis. The presence and physiological relevance of BAT in
adult humans were believed to be marginal. In recent years,
however, it has been realized that a significant number of
adult humans possess active BAT [2, 3] and that cold induces
the activation of oxidative metabolism in BAT [4]. Moreover,
an inverse relationship between BAT activity and shivering
has been demonstrated in humans exposed to cold [5].
When the human body is exposed to cold and the
homeostatic mechanisms are unable to compensate the heat
that is being lost , there is a drop in body temperature.
The symptoms and consequences of hypothermia may vary
depending on the degree of hypothermia and have been
associated according to the four degrees or stages of severity:
mild 32–35∘C; moderate, 28–32∘C; severe, 20–28∘C; and
profound at less than 20∘C [6]. Other authors such as Marion
et al. [7] and Gentinello [8] included an additional category,
the extreme hypothermia, when the temperature falls below
14∘C.
Symptoms of mild hypothermia may be vague [1]
and some physiological responses to preserve heat can be
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observed with sympathetic nervous system excitation pro-
voking shivering, hypertension, tachycardia, tachypnea, and
vasoconstriction. Additional symptoms that may be present
are cold diuresis, mental confusion, hepatic dysfunction, and
hyperglycemia due to the decrease in glucose uptake by cells,
a decrease in insulin secretion, and impaired tissue sensitivity
to insulin [6].
Moderate low body temperature results in a stronger
shivering. Due to a slower speed in nervous transmission
and lower brain blood flow, mild confusion, impaired mental
skills, and muscle misscoordination become apparent, and
movements are slow and labored [9]. Skin blood vessels con-
tract further as the body focuses its remaining resources on
keeping the vital organs warm. Microcirculation alterations
cause a reduction of blood flow, red cell sedimentation, and
an increase in blood viscosity (2%per degree heat loss), which
increases the reduced availability of oxygen in the tissues
leading to a hypoxic situation and acidosis [10].
Severe hypothermia occurs with decreasing temperature,
and other physiological systems begin to fail: heart rate,
breathing rate, and blood pressure decrease all. The hypotha-
lamus is not controlling anymore the thermoregulation. This
results in a heart rate of about 30 beats per minute with
a temperature of 28∘C in humans [6]. Mental skills and
motor coordination are still more impaired with a difficulty
in speaking, sluggish thinking, incoherent behavior, and
amnesia starting to appear; lack of skill in using hands, poor
muscle coordination, difficulties in walking, and stumbling
are also usually present.
We must also consider the general effects of hypothermia
that occur in all categories, such as a decrease in metabolism
and oxygen consumption. The basal and activity metabolic
rates decrease between 3 and 7% by the fall of 1 degree
Celsius [7]. The Q10 or relative change in metabolic rate for
every 10 degrees of change in body temperature is about
2.3 [11]. Prakash [12] mentions that oxygen consumption is
reduced by 6% for each degree drop in body temperature.
Arrhythmias are also often accompanied by frequent atrial
fibrillation, bleeding, and coagulopathy due to mismatches
in platelet function [8]. Hypothermia has a strong immuno-
suppressive effect, increasing the risk of infections, specially
wound infections and pneumonia [13, 14]. On respiratory
function, hypothermia is also inhibitory, initially leading
to a rapid shallow breathing followed by a bradypnea,
bronchospasm, and hypoventilation. However, the oxygen
partial pressure is stable during hypothermia, indicating that
both cardiac output and oxygen consumption, despite being
reduced, are actually sufficient to meet metabolic needs.
A further problem derives from the subsequent pro-
cess of rewarming that necessarily follows in some time
hypothermia. Rewarming is a challenge for homoeothermic
organisms: a rise in temperature implies an increase in
metabolism and oxygen demand by tissues. A circulatory
collapse characterized by a decreased cardiac output and
blood pressure has been described during the rewarming
phase in victims of an accidental hypothermia [15]. The final
result will be influenced by the rate of rewarming. Polderman
and Callaghan [16, 17] advise rates of 0.2–0.5∘C/h for cardiac
arrest and 0.1-0.2∘C/h for other pathologies. After induction
of severe hypothermia (20∘C) and rewarming in rats a high
mortality was found when rewarming at 0.35∘C/min, while
all animals survived at a rate of 0.25∘C/min [18].
1.2.TheTherapeuticUse ofHypothermia. Despite the undesir-
able physiological effects of hypothermia, its therapeutic use
has been known since ancient times and more recently has
been revalued [13, 19, 20].
Mild to moderate hypothermia (35 to 32∘C) appears to be
useful in preventing tissue damage, cell protection [21], and
survival [22]. Several international organizations such as the
American Health Association and the International Liaison
Committee on Resuscitation have recommended the use of
therapeutic hypothermia in patients with cardiac pathologies
among others [23]. In the European Resuscitation Council
Guidelines [24, 25], induced hypothermia is included in the
standard recommendations after cardiopulmonary resuscita-
tion.
Molecular and cellular pathways regulated by hypother-
mia have been recently reviewed [26]. Many studies on
the protective effects of hypothermia have been conducted
in cell cultures, for example, in endothelial cells [27], in
isolated organs such as heart [28], and in experimental
animals [29]. In this regard, the information obtained from
studying hibernating mammals is particularly relevant. The
hibernating mammals survive cyclical periods of torpor and
arousal with large fluctuations in body temperature. It has
been suggested that hibernation mitigates apoptosis [30] by
an elevation of antiapoptotic [31] or prosurvival [32] proteins.
The elucidation of the molecular mechanisms occurring
during these periods of hypothermia can be helpful in future
human clinical studies of therapeutic hypothermia.
Some of the therapeutic and side effects of the application
of hypothermia are well documented [36]. However, it is
necessary to clarify the cellular mechanisms induced by cold
to enable its safe clinical use. In the present work we discuss
the role of RONS and antioxidants during hypothermia and
rewarming, and we hypothesize that if the beneficial effects
of therapeutic hypothermia could be due to RONS acting as
signaling molecules.
2. Hypothermia and Oxidative Stress
2.1. Tissue Oxygen Availability and Acid/Base Regulation dur-
ing Hypothermia. As we mentioned above, the decrease in
temperature affects all the physiological systems of the body.
The hypothermia process is associated with a reduction of
blood flow [37]. It is well known that cold exposure decreases
renal [38] and liver flow [39, 40]. We analyzed the correlation
between portal vein flows (PVF) as temperature drops from
37∘C to 22∘C in rats [33]. Figure 1 shows how the cooling
caused a decrease in PVF andwe can see that the curve of PVF
versus temperature fits a second order polynomial regression.
This biphasic curve suggests that a homeostatic mechanism
is working in opposition to hypothermia and is capable
of maintaining PVF in mild and moderate hypothermia
close to normal ranges. However, the physiological regulator
mechanism can not control body temperature when this
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Figure 1: Portal vein flow (PVF) versus body temperature in
anesthetized rats during cooling. After induction of anesthesia,
animals were placed on a cooling/rewarming table. Animals were
cooled at a mean rate of −0.25∘C/min. Rats (𝑛 = 6) were intubated
through the trachea and mechanically ventilated with room air. The
portal vein circulationwas analyzed using a laser-doppler blood flow
meter by means of a fiberoptic probe positioned around the portal
vein. The curve was calculated by taking the mean of PVF values
of all the animals (referred to as a percentage of the starting point)
at 5min intervals and plotting each of these as one point. Note that
blood flow is kept close to basal value during the beginning of the
cooling (unshaded area) but it dropped drastically under 30 degrees
of body temperature (shaded area) [33].
decreased towards more severe hypothermic value (below
30∘C). Redistribution of blood flow and microcirculation
disturbances induced by hypothermia can limit tissue oxygen
availability [41].
In addition to changes in the availability of oxygen,
hypothermia can affect other blood parameters like partial
pressure of gases, electrolytes, and acid/base regulation.
Alterations in pH are initially corrected by ventilation and
then, in a slower process, by kidneys. When hypothermia
develops the pH is altered. In fact, the combination of
hypothermia and acidosis is seen as a critical point in the
injured by trauma [42]. The failure of respiratory and/or
renal functions, acid/base regulation, and ion regulatory
mechanisms has been suggested as critical during severe
hypothermia [43].
The hemoglobin oxygen affinity actually increases in
hypothermia, and a restricted oxygen discharge in tissues
could be expected. A reduction in the supply of oxygen to
tissues has been reported during mild hypothermia (34∘C)
[10]. Although lack of oxygen could drive cells to anaerobic
metabolism in order to maintain ATP production, cardiac
lactate [39], liver lactate [40], and blood lactate [44] kept
constant after hypothermia; suggesting that, even though
blood supply to tissues is diminished in cold, the oxygen
demand also drops in proportion to the lower metabolic
requirements.
Accidental or therapeutic hypothermia implies an
unavoidable process, the rewarming phase. The rise in
temperature will increase metabolism and oxygen demand
by tissues. Thus, a mismatch between blood flow restoration
and tissue metabolism would cause anaerobic glycolisis,
acid overload, and the release of metabolites into the blood
stream [40].
As wementioned above, an important consequence of the
hypothermia and rewarming process would be the reduction
in oxygen delivery to some tissues. The effect of this decrease
in cellular oxygen could resemble a hypoxic condition in
which oxygen free radicals are produced [45] and released
from the mitochondria [46].
2.2. Oxidant/Antioxidant Balance in Hypothermia Rewarm-
ing. The reduced availability of oxygen in hypothermia
may result in the accumulation of reducing equivalents in
the mitochondrial electron transport chain, enhancing the
production of reactive oxygen and nitrogen species (RONS)
and the resulting oxidative stress, that is, the oxidation and
subsequent functional impairment of lipids, proteins, and
nucleic acids [47]. Similar to what has been described for
hypoxia-reoxygenation process [48], the return to physio-
logical conditions of temperature may lead to an increased
production of oxygen free radicals.
It has been reported that hypothermia (24∘C to 28∘C)
can induce an increase in oxidative stress [49–51] but also
a decrease in RONS [52, 53]. Using a model of isolated
liver preservation, it has been reported that liver perfusion
performed at 20∘C can enhance the functional integrity of
steatotic livers when compared to perfusion at 8∘C and 4∘C
[54]. Perfusion at 20∘C also led to a marked improvement in
hepatic preservation, cell viability, and reduction in oxidative
stress parameters [54, 55]. When considering the effects of
hypothermia on oxidative stress, the disparity in the results
found could be due to different length of exposition to cold
and to the temperature applied.
In physiological conditions there is a balance between
the factors that promote the formation of free radicals and
the levels of antioxidants. RONS are scavenged by enzymatic
antioxidants like superoxide dismutase, glutathione peroxi-
dase, and catalase [56] and by small molecular antioxidants
such as reduced glutathione (GSH). GSH appears to be essen-
tial for the activation and maintenance of cellular defenses
against oxidative stress, since it provides the substrate for glu-
tathione peroxidase to detoxify peroxides. In rats acclimated
to cold [57] lipid peroxidation increased and the activities and
levels of antioxidants decreased in the erythrocytes.
We have studied the oxidant/antioxidant levels in vivo in
rats at severe hypothermia and rewarming. After induction of
anesthesia, animalswere placed on a cooling/rewarming table
and were mechanically ventilated with room air. Animals
were cooled at a mean rate of −0.25∘C/min until they achieve
22∘C. After one hour at hypothermia rats were rewarmed at
a rate of 0.35∘C/min to 37∘C. Hypothermia and rewarming
increased nitric oxide in plasma and liver and lipid per-
oxidation in plasma (Table 1). The erythrocyte antioxidant
enzymatic activity decreased in hypothermia (superoxide
dismutase and catalase) and rewarming (glutathione perox-
idase). Results regarding the role of GSH in the hypothermia
and rewarming process deserve amore detailed analysis. GSH
appears to be essential for the activation and maintenance of
cellular defenses against oxidative stress [58] and is the main
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Table 1: Oxidant/antioxidant status in rats after severe hypothermia and rewarming.
Arterial Blood Liver
Sham Hypothermia Rewarming Sham Hypothermia Rewarming
NOx 10.76 ± 0.52 14.68 ± 0.59∗∗∗ 12.57 ± 0.48∗,+ 1.28 ± 0.06 1.56 ± 0.06∗ 2.00 ± 0.10∗∗∗,++
TBARS 3.60 ± 0.10 4.66 ± 0.36∗ 4.46 ± 0.20∗ 3.93 ± 0.36 4.32 ± 0.43 3.30 ± 0.31
GSH 221.02 ± 5.53 230.61 ± 8.24 140.42 ± 7.50∗∗∗,+++ 4.56 ± 0.37 4.50 ± 0.17 2.91 ± 0.17∗∗∗,+++
SOD 100 ± 3.58 82.86 ± 1.95∗∗ 85.81 ± 4.35∗ 100 ± 3.11 102.80 ± 3.59 100.80 ± 5.73
GPx 100 ± 3.09 101.94 ± 3.38 57.41 ± 7.28∗∗∗,+++ 100 ± 2.91 99.54 ± 6.87 92.27 ± 2.16
CAT 100 ± 7.54 71.45 ± 4.39∗∗ 61.18 ± 4.73∗∗∗ 100 ± 5.34 90.50 ± 6.22 90.34 ± 2.90
Animals were assigned to 3 groups of 6 individuals each. Sham animals were killed after anesthesia. In hypothermia group anesthetized animals were cooled
for one hour at a mean rate of −0.25∘C /min to achieve 22∘C. Then they were killed. The rewarming group was cooled as described above and then it was
rewarmed at a rate of 0.35∘C/min to 37∘C. Oxidative indicators were the concentration of nitric oxide derivatives (NOx) in plasma (nM) and liver (nmol/mg
protein) and thiobarbituric acid-reactive substances (TBARS) in plasma (nM) and liver (nmol/mg protein). Antioxidant status was evaluated as thiols in plasma
(GSH, 𝜇M) and in liver (GSH, 𝜇mol/g liver). The enzymatic antioxidant activities of Cu-Zn superoxide dismutase (SOD), glutathione peroxidase (GPx), and
catalase (CAT) were evaluated in erythrocytes and in liver and were expressed as a percentage of corresponding sham value. Data is mean ± SEM of six animals.
Significantly different from corresponding sham values: ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001. Significantly different from corresponding hypothermia
values: +𝑃 < 0.05, ++𝑃 < 0.01, and +++𝑃 < 0.001.
thiol-disulfide redox buffer in the cell. The data presented
in Table 1 indicate that after hypothermia GSH levels are
preserved in plasma and also in liver, which is the most
important organ for GSH synthesis and exportation into the
plasma. In contrast, rewarming results in a high consumption
of GSH and, in erythrocytes, a dramatic reduction in the
glutathione peroxidase activity. It has been reported that
the protective effect of hypothermia against hypoxia-induced
damage in vitro could be improved with the addition of
catalase to the cellularmedium [59]. In view of our results, the
administration of glutathione seems more advisable, at least
in vivo situations.
3. RONS and Apoptosis
With regard to radical generation there is increasing evidence
that cell death is associated with an increase in intracellular
RONS [69–72].
Apoptosis, or programmed cell death, is an accurately
regulated mechanism whereby the cell actively uses a genet-
ically controlled program to kill itself, with ATP being
required to accomplish this process. Apoptosis is a key
process that is involved in maintaining tissue homeostasis
by removing senescent, genetically damaged cells or cells
damaged by disease or noxious agents. Apoptosis is induced
by two main ways: the activation of death receptors (the
extrinsic pathway) or involving the mitochondria (the intrin-
sic pathway). In the extrinsic pathway signal arrives when
“death ligands” such as TNFa, TRAIL, Apo3L, and Fas ligand
(Fas L), bind to their specific membrane receptors causing
their intramembrane domains to propagate the death signal
intracellularly. RONS have been established as key partici-
pants in Fas-induced cell death [70, 71]. In themitochondrial-
mediated pathway the signal is originated intrinsically [73] by
the stress produced in organelles like the mitochondria (e.g.,
RONS) or endoplasmic reticulum (e.g., excess of misfolded
proteins), inducing the release of pro-apoptotic factors into
the cytosol or inhibiting antiapoptotic molecules that will
ultimately trigger apoptosis.
Regardless of the signal origin, the formation of a
permeability transition pore at contact sites between the
mitochondrial outer and inner membranes and the release of
cytochrome c into the cytosol are considered the “points of
no return” in apoptotic process. Thus, mitochondria are the
central organelle in the execution of apoptosis [74]. RONS
generation in mitochondria increased prior to the onset of
apoptosis [70], and the apoptotic process could be stopped
by the addition of antioxidants [72].
4. The Role of RONS as Signaling Molecules
We must bear in mind that the formation of RONS is
a physiological process. Indeed, RONS play a critical role
in the cell, while at relatively high concentrations they
becomeharmful; low levels can promote cell proliferation and
survival [75, 76]. These dual effects of RONS, depending on
their concentration, could explain why hypothermia through
RONS generation sometimes gets involved in pathologies
while when induced previous to or concomitant to an
acute damage leads to a cellular protection. Some of the
studies regarding the protective effects of hypothermia on
oxidant/antioxidant parameters and against different types of
injury are summarized in Table 2. While comparing different
temperature levels in different species and affecting various
tissues, some general conclusions can be drawn. Hypother-
mia increases oxidative stress, NO levels, and the GSH.When
hypothermia is used in a model of injury, like ischemia or
hypoxia (known to increase oxidative damage), paradoxically
it causes a decreased oxidative stress and the maintenance or
improvement of the antioxidant status.
Recently, we have described that the oxidative stress indi-
cators were attenuated in rats with an acute damage (severe
hypoxia) at hypothermia (at 22∘C) compared with animals
at normothermia (at 37∘C) [33]. Similarly, in cardiomyocytes
[77] it was described a hypothermic protection through
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Table 2: Selected data showing the protection induced by the experimental hypothermia. This table summarizes information about the
impact of the experimental hypothermia on oxidant/antioxidant parameters. Despite the different levels of hypothermia, animal species,
tissues, or injury models, the overall effects are as follows. First hypothermia by itself induces an increase in oxidative stress markers and in
the reduced glutathione. Second, if hypothermia is applied during another injury there is a decrease in oxidative stress and the maintenance
or improvement of antioxidants.
HT level
(∘C) Specie Target
Injury
model
Oxidative stress
indicator
Injury
effects
HT alone
effects
HT-
induced
protection
Comments Reference
17 Guinea pig HeartIn vitro I/R
ROS generation
NADH+
Mitochondrial Ca++
↑
↑
↑
↑
↑
↑
↓
↓
↓
[28]
20–22 Rat In vivo Hx(10% O2)
Plasma TBARS
Liver TBARS
Liver GSH/GSSG
↑
↑
↓
↑
=
↑
↓
↓
↑
Intrahypoxic
HT
Ventilatory
support
[33]
23-24 Rat In vivo — CatalaseVitamin E
ND
ND
↓
↓
ND
ND
Ventilatory
support not
provided
[46]
25 Pig ArteryIn vitro — NO synthesis ND ↑ ND [60]
26 Rat In vivo I/R
TBARS
SOD
Catalase
=
=
↑
=
↑
=
↓
=
↓
Intraischemic
HT followed by
reperfusion at
37∘C
[61]
30–32 Rat IntestineIn vivo I/R
TBARS
GSH/GSSG
Plasma NOx
↑
↓
↑
=
=
=
↓
↓
↓
Ventilatory
support using a
mixture of
O2/NO
∙
[62]
32 Rat In vivo
Heatstroke
(40∘C)
O
2
∙− generation
MDA in liver
↑
↑
ND
ND
↓
↓
[63]
Mouse CA1hippocampus MCAO
NOS expression
CaM-KII
=
↓
ND
ND
=
↑
HT increases
CaM-KII [64]
33–35
Pig Brain MCAO GSHN-Acetyl aspartate
↓
↓
ND
ND
↑
↑
Decreasing
NAA = cell
dysfunction and
neuronal loss
[65]
Rat In vivo MCAO iNOS expressionNitrotyrosine
↑
↑
ND
ND
↓
↓
Intraischemic
HT is more
effective than
postischemic
HT
[35, 66]
34 Rat Isolated LiverIn vitro Ischemia Efflux rate TBARS ↑ = ↓ [67]
35 Mouse BrainIn vivo ALF GSH/GSSG ↓ ND ↑
GSH/GSSG
Incremented
over sham
values
[68]
ALF: acute liver failure.
CaM-KII: Ca2+/calmodulin protein kinase II.
GSH/GSSG: reduced/oxidized glutathione.
HT: hypothermia.
Hx: hypoxia.
I/R: ischemia/reperfusion.
MCAO: middle cerebral artery occlusion.
MDA: malondialdehyde.
ND: not described.
NOS: nitric oxide synthase.
NOx: nitric oxide derived products.
O
2
∙−: superoxide radical.
SOD: superoxide dismutase.
TBARS: thiobarbituric acid-reactive substances.
↑, ↓: increase, decrease, respectively.
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Figure 2: Modulation of apoptosis by hypothermia. After a serious insult the cell can trigger apoptosis, a highly regulated cell death
mechanism. Intrinsic Pathway. Hypothermia increases ATP stores and slows ion channels then maintaining the integrity of the membranes.
Hypothermia applied together or immediately after injury decreases the production of ROS. These events limit the rupture of the outer
mitochondrial membrane and the release of proapoptotic molecules like cytochrome c into the cytosol. The hypothermia-induced increase
in nitric oxide also avoids cytochrome c release and it is even reported that early NO production can exert a negative feedback regulation of
iNOS [34]. Moreover, iNOS transcription activated byNF𝜅Bwas diminished after hypothermia [35]. Since catalase is absent inmitochondria,
maintaining GSH redox cycle is critical to avoid H
2
O
2
accumulation.There is abundant evidence that hypothermia keeps GSH pool. Extrinsic
Pathway. It was found that hypothermia decreases the affinity of the death ligands-death receptors, with the consequent inhibition of the
initiator caspases like caspase-8 or the NF𝜅B-family molecules.
a reduction in the hydrogen peroxide-induced damage when
cardiomyocytes were incubated at 20∘C for 20 minutes. After
rewarming, hypothermic cardiomyocytes showed a higher
rate of reduction of intracellular reactive oxygen species
compared to normothermically maintained cardiomyocytes.
In addition, the neuroprotective effects of hypothermia had
also been described in amodel of oxygen-glucose deprivation
in hippocampal cultures at 31∘C [78] showing that the protec-
tion acts at moderate hypothermia, which may explain the
protection observed in the range of therapeutic hypothermia
(32–35∘C) used in humans.
It has been exhaustively reported that a brief episode
of ischemia makes organs (brain, heart, liver, and kidney)
remarkably resistant to a subsequent ischemia, phenomenon
know as ischemic preconditioning. The mechanisms of sig-
naling pathways in cardiac ischemic preconditioning have
been recently reviewed [75] and it is believed that RONS
play an important role in the mechanisms of preconditioning
and protection. During the early phase of preconditioning
ROS and NO production afford protection against further
damage in cerebral ischemia [79, 80] and in cardiomyocytes
ischemia [81]. The production of adenosine during ischemic
preconditioning could mediate the protective effects [82].
Adenosine increases energy production through increased
glycolytic flux. Furthermore, it has been observed that
adenosine inhibits the release of oxygen radicals during
ischemia and reperfusion in myocardial ischemia, thus limit-
ing endothelial cell injury [83]. The production of adenosine
during ischemic preconditioning is dependent on the levels of
hypoxia-inducible factor 1 (HIF-1) [84] whichmediates many
adaptive responses to hypoxia by regulating the expression
of genes involved in glycolysis, mitochondrial function, cell
survival, and resistance to oxidative stress [85]. Interestingly,
activation of HIF-1𝛼 is correlated with better protection of
fatty liver grafts after cold storage [86]. However, the addition
of an inhibitor of NO in the preservation medium reversed
that protection. This highlighted the role of NO in liver
preservation.
As referred to hypothermia, our results [33] and others
[77–80] lead us to propose the hypothesis that hypother-
mia through the generation of RONS and increasing GSH
can induce protective mechanisms. The most remarkable
of hypothermia is that protection is observed both when
induced prior to injury, as a preconditioning model (exper-
imental hypothermia), and when applied after damage (ther-
apeutic hypothermia). In the latter case, the sooner hypother-
mia is applied, the better prognosis patient will have [17, 87].
5. Role of RONS in the Beneficial Effects of
Therapeutic Hypothermia
Therapeutic hypothermia has been used in the critically
ill patients, and there is also abundant evidence from
animal models of the protection induced by hypothermia
when applied within minutes following ischemic damage
(see Table 2). So far, the protective effects of hypothermia are
believed to be a consequence of a reduction in the cellular
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metabolism and the retardation of destructive enzymatic
reactions and the concomitant oxygen needs, thus conserving
ATP levels [88].
More recently, the beneficial effects of hypothermia, when
applied to prevent an ischemic episode, included a trigger
level of RONS that can act as a mechanism for induction of
signaling pathways and the modulation of the extrinsic and
intrinsic pathways of apoptosis (see Figure 2). Hypothermia
does not simply block cell signaling pathway of apoptosis and
necrosis but selectively upregulates some protective genes
after ischemia [89]. Many experimental assays showed that
when hypothermia is applied during an ischemia or hypoxia
episode, it is able to inhibit proapoptotic molecules and to
induce an increase in antiapoptotic ones in ischemic tissues
[90, 91].
Because of these different mechanisms of action, it can
be suggested that hypothermia may be protective in many
organs and against many kinds of injury.
6. Conclusion
The generation of RONS is a typical feature of hypothermia
and more prominent in rewarming. There is increasing
evidence showing that the beneficial effects of hypothermia
included a trigger level of RONS that can act as a mechanism
for induction of signaling pathways and the modulation of
apoptosis.
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